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Increasingly, economic evidence generated alongside clinical
trials is being used to inform decisions concerning the adoption
of new health-care technologies at national or jurisdictional level.
A key issue relating to the use of this type of evidence is the extent
to which the economic (and some would argue the clinical)
results of a study conducted in one (or more) jurisdiction(s) are
applicable to another, where the latter did not take part in the
study.
Factors such as differences in relative prices, availability
of resources, epidemiological context, and health-care system’s
characteristics paired with the inherently jurisdiction-speciﬁc
nature of the resource allocation decision-making process mean
that the study data will almost inevitably need to be subject to
some form of modeling in the attempt to transfer the results of
the trial from one jurisdiction to another.
The methods that have been proposed to address this trans-
ferability issue have often been relatively ad hoc [1], with the
obvious consequence that the methodological literature in this
area has evolved somewhat nonlinearly and inconsistently over
time. A major determinant of this may have been the absence of
clear guidance on what constitutes an appropriate methodology
on 1) how to assess the extent to which cost-effectiveness data are
transferable between jurisdictions; and 2) what methods should
be used to customize the analysis to a speciﬁc decision-making
context.
We are therefore grateful to Drummond et al. for the publi-
cation of the ISPOR task force report on economic data trans-
ferability [2] in the current issue of Value in Health. The authors
should be commended for a timely, well-organized, and clearly
written report which, it is hoped, will be used to guide the
selection of appropriate methods for analysis and reporting of
multinational economic data when the objective is to produce
cost-effective estimates for jurisdiction-speciﬁc decision-making.
There are various entities that are expected to beneﬁt from
following the recommendations described in this report. One
would expect that research projects which aim to produce more
transferable evidence would be of high value to international
funding organizations. Similarly, when designing and analyzing
the economic elements of their multinational trials, the pharma-
ceutical and medical device industry may ﬁnd the methods pro-
posed by Drummond et al. [2] useful to enhance their chances of
successful reimbursement submissions in different jurisdictions.
Methods for the analysis of cost-effectiveness data are devel-
oping fast. This is probably (but not exclusively) thanks to the
fact that a growing number of jurisdictions now requests eco-
nomic data in support of their decision-making procedures for
the pricing and/or reimbursement of health technologies [3,4].
The presence of a clear requirement in such guidelines regarding
the need to assess the extent to which economic data are trans-
ferable is a fundamental incentive to the application and further
development of the method described by Drummond et al. in this
report. Nevertheless, with the exception of the Canadian [5],
most jurisdiction-speciﬁc guidelines for economic evaluation are
still vague on the matter.
We hope that the publication of this ISPOR task force report
will help stimulate further debate between regulators, the indus-
try, and the academia on the correct use of multinational
economic data for jurisdiction-speciﬁc decision-making.
References
1 Sculpher MJ, Pang FS, Manca A, Drummond MF. Generalisability
in economic evaluation studies in health care: a review and case-
studies. Health Technol Assess 2004;8:1–206.
2 Drummond M, Barbieri M, Cook J, Glick HA. Transferability of
economic evaluations across jurisdictions: ISPOR good research
practices task force report. Value Health 2009;12 (in press).
3 Hjelmgren J, Berggren F, Andersson F. Health economic guide-
lines: similarities, differences and some implications. Value Health
2001;4:225–50.
4 Tarn TY, Smith MD. Pharmacoeconomic guidelines around the
world. ISPOR CONNECTIONS 2004;10:5–12.
5 CADTH. Guidelines for the Economic Evaluation of Health
Technologies. Ottawa, Canada: Canadian Agency for Drugs and
Technologies in Health, 2006.
Address correspondence to: Andrea Manca, Centre for Health Economics,
The University of York, Alcuin College, A Block, York YO10 5DD, UK.
E-mail: am126@york.ac.uk
10.1111/j.1524-4733.2008.00493.x
Volume 12 • Number 4 • 2009
V A L U E I N H E A LT H
© 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/09/407 407 407
